Acute myeloid leukemia (AML) is characterized by the blockade of hematopoietic differentiation and cell death, and interesting work from the Jost laboratory demonstrated that receptor-interacting protein kinase 3 (RIPK3) promotes the differentiation of leukemia-initiating cells by activating the inflammasome. This evidence concerns the gene RIPK3 and acute myeloid leukemia.